Owais Sanaullah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Owais Sanaullah has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Abedin Samadi
Kabul University of Medical Sciences Kabul Afghanistan
1 shared publication - Ahmed Asad Raza
Department of Medicine Jinnah Sindh Medical University Karachi Pakistan
1 shared publication - Ali Wajahat
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Ammad Uddin
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Anusha Tharwani
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Fnu Komal
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication
Latest Publications
- 9 September 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Fremanezumab in Episodic Migraine: A Systematic Review and Meta-analysis
Background: Fremanezumab, a calcitonin gene-related peptide monoclonal antibody, is approved for migraine prevention, yet evidence specific to episodic migraine remains limited. We synthesized randomized evidence on its efficacy and safety. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420261385104), we systematically searched PubMed, Embase, and Scopus from inception to June 5, 2026, for placebo-controlled randomized controlled trials (RCTs) evaluating fremanezumab for episodic migraine prevention. Primary outcomes were the ≥50% responder rate and change in monthly migraine days. Random-effects meta-analyses were performed, and risk of bias was assessed using the Cochrane RoB 2 tool. Results: Four RCTs including 1764 participants were included. Fremanezumab significantly increased the ≥50% responder rate (risk ratio: 1.81, 95% CI: 1.53-2.15) and reduced monthly migraine days (mean difference: −1.98, 95% CI: −2.93 to −1.03), headache days, acute medication-use days, and migraine-related disability. Overall safety was comparable to placebo, with no significant differences in treatment-emergent adverse events, serious adverse events, or treatment discontinuations; injection-site induration occurred more frequently with fremanezumab. Relevance to Patient Care and Clinical Practice: This meta-analysis strengthens the evidence supporting fremanezumab as an effective and generally well-tolerated preventive therapy for episodic migraine. The demonstrated reductions in migraine frequency, disability, and acute medication use, together with flexible monthly and quarterly dosing, support its use in appropriately selected patients and may facilitate individualized treatment decisions by clinicians and pharmacists. Although the inclusion of pediatric data expands the current evidence base, these findings should be interpreted cautiously because they are derived from a single randomized trial. Conclusion: Fremanezumab is an effective and generally well-tolerated preventive treatment for episodic migraine. Evidence is robust in adults, whereas pediatric findings remain preliminary and warrant confirmation in future randomized trials.
- 9 September 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Fremanezumab in Episodic Migraine: A Systematic Review and Meta-analysis
Background: Fremanezumab, a calcitonin gene-related peptide monoclonal antibody, is approved for migraine prevention, yet evidence specific to episodic migraine remains limited. We synthesized randomized evidence on its efficacy and safety. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420261385104), we systematically searched PubMed, Embase, and Scopus from inception to June 5, 2026, for placebo-controlled randomized controlled trials (RCTs) evaluating fremanezumab for episodic migraine prevention. Primary outcomes were the ≥50% responder rate and change in monthly migraine days. Random-effects meta-analyses were performed, and risk of bias was assessed using the Cochrane RoB 2 tool. Results: Four RCTs including 1764 participants were included. Fremanezumab significantly increased the ≥50% responder rate (risk ratio: 1.81, 95% CI: 1.53-2.15) and reduced monthly migraine days (mean difference: −1.98, 95% CI: −2.93 to −1.03), headache days, acute medication-use days, and migraine-related disability. Overall safety was comparable to placebo, with no significant differences in treatment-emergent adverse events, serious adverse events, or treatment discontinuations; injection-site induration occurred more frequently with fremanezumab. Relevance to Patient Care and Clinical Practice: This meta-analysis strengthens the evidence supporting fremanezumab as an effective and generally well-tolerated preventive therapy for episodic migraine. The demonstrated reductions in migraine frequency, disability, and acute medication use, together with flexible monthly and quarterly dosing, support its use in appropriately selected patients and may facilitate individualized treatment decisions by clinicians and pharmacists. Although the inclusion of pediatric data expands the current evidence base, these findings should be interpreted cautiously because they are derived from a single randomized trial. Conclusion: Fremanezumab is an effective and generally well-tolerated preventive treatment for episodic migraine. Evidence is robust in adults, whereas pediatric findings remain preliminary and warrant confirmation in future randomized trials.
- Open Access
- 15 May 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Efficacy of transcranial direct current stimulation on motor and cognitive functions in patients with multiple sclerosis: a systematic review and meta-analysis
Background: Multiple Sclerosis (MS) is a chronic neurological disorder affecting 2.8 million individuals worldwide, characterized by motor dysfunction and cognitive impairment that remain poorly addressed by pharmacological interventions alone. Transcranial Direct Current Stimulation (tDCS) has emerged as a promising non-invasive neuromodulation technique for symptom management in MS patients. Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy of tDCS in improving motor and cognitive functions in patients with MS, and to assess its safety profile. Methods: A comprehensive literature search was conducted across PubMed, Scopus, EMBASE, Wiley Online Library, and Google Scholar databases. Studies were selected based on PICOS criteria, including randomized controlled trials and quasi-experimental studies involving adults (≥ 18 years) with all types of MS receiving tDCS interventions. Methodological quality was assessed using RoB 2.0 and ROBINS-I. Meta-analyses were performed using RevMan 5.4.1 with random-effects models for outcomes with substantial heterogeneity and fixed-effects models where I 2 = 0%. Additionally, the protocol was prospectively registered with the Open Science Framework. Results: Twenty-two studies published between 2015 and 2025 were included in this review. Meta-analysis revealed that tDCS significantly improved information processing speed (SDMT: MD = 7.71, 95% CI: 1.60—13.82, p = 0.01) and functional mobility (TUG: MD = -1.03 s, 95% CI: -2.08—0.02, p = 0.05). While individual studies showed improvements in gait speed and balance, pooled analyses for these outcomes did not reach statistical significance (gait speed: MD = 0.16 m/s, 95% CI: -0.07—0.38, p = 0.18; Berg Balance Scale: MD = 1.18, 95% CI: -2.03—4.39, p = 0.47). Qualitative analysis revealed consistent improvements in manual dexterity, working memory, executive function, and complex attention. Additionally, no serious adverse events were reported across studies; mild and transient side effects (e.g., tingling, itching) were noted, and completion rates were high (98% in studies that reported them). Conclusion: This systematic review provides preliminary evidence supporting tDCS as a potentially beneficial adjunctive intervention for MS patients, particularly for cognitive processing speed enhancement based on two small studies. While individual studies reported motor improvements, pooled meta-analyses for gait speed and balance failed to demonstrate statistical significance, indicating insufficient evidence for definitive motor benefits despite positive signals in individual trials. The substantial limitation of small study numbers per meta-analysis (2—6 studies), combined with limited MS subtype-specific data in most studies, significantly constrains confidence in these findings and limits assessment of external validity across different MS populations. Larger, standardized, multi-center randomized controlled trials with adequate subgroup representation and extended follow-up periods are essential to establish clinical significance and treatment durability.
- 15 May 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Open AccessEfficacy of transcranial direct current stimulation on motor and cognitive functions in patients with multiple sclerosis: a systematic review and meta-analysis
Background: Multiple Sclerosis (MS) is a chronic neurological disorder affecting 2.8 million individuals worldwide, characterized by motor dysfunction and cognitive impairment that remain poorly addressed by pharmacological interventions alone. Transcranial Direct Current Stimulation (tDCS) has emerged as a promising non-invasive neuromodulation technique for symptom management in MS patients. Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy of tDCS in improving motor and cognitive functions in patients with MS, and to assess its safety profile. Methods: A comprehensive literature search was conducted across PubMed, Scopus, EMBASE, Wiley Online Library, and Google Scholar databases. Studies were selected based on PICOS criteria, including randomized controlled trials and quasi-experimental studies involving adults (≥ 18 years) with all types of MS receiving tDCS interventions. Methodological quality was assessed using RoB 2.0 and ROBINS-I. Meta-analyses were performed using RevMan 5.4.1 with random-effects models for outcomes with substantial heterogeneity and fixed-effects models where I 2 = 0%. Additionally, the protocol was prospectively registered with the Open Science Framework. Results: Twenty-two studies published between 2015 and 2025 were included in this review. Meta-analysis revealed that tDCS significantly improved information processing speed (SDMT: MD = 7.71, 95% CI: 1.60—13.82, p = 0.01) and functional mobility (TUG: MD = -1.03 s, 95% CI: -2.08—0.02, p = 0.05). While individual studies showed improvements in gait speed and balance, pooled analyses for these outcomes did not reach statistical significance (gait speed: MD = 0.16 m/s, 95% CI: -0.07—0.38, p = 0.18; Berg Balance Scale: MD = 1.18, 95% CI: -2.03—4.39, p = 0.47). Qualitative analysis revealed consistent improvements in manual dexterity, working memory, executive function, and complex attention. Additionally, no serious adverse events were reported across studies; mild and transient side effects (e.g., tingling, itching) were noted, and completion rates were high (98% in studies that reported them). Conclusion: This systematic review provides preliminary evidence supporting tDCS as a potentially beneficial adjunctive intervention for MS patients, particularly for cognitive processing speed enhancement based on two small studies. While individual studies reported motor improvements, pooled meta-analyses for gait speed and balance failed to demonstrate statistical significance, indicating insufficient evidence for definitive motor benefits despite positive signals in individual trials. The substantial limitation of small study numbers per meta-analysis (2—6 studies), combined with limited MS subtype-specific data in most studies, significantly constrains confidence in these findings and limits assessment of external validity across different MS populations. Larger, standardized, multi-center randomized controlled trials with adequate subgroup representation and extended follow-up periods are essential to establish clinical significance and treatment durability.